Drug Profile

CID 078

Alternative Names: CID-078

Latest Information Update: 19 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Circle Pharma
Class Antineoplastics; Macrocyclic compounds; Peptides
Mechanism of Action Cyclin A inhibitors; Cyclin B inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Small cell lung cancer
New Molecular Entity Yes

Highest Development Phases

Phase I Solid tumours

Most Recent Events

16 Jun 2025 CID 078 receives Orphan Drug status for Small cell lung cancer in USA
10 Dec 2024 Pharmacodynamics and adverse events data from a preclinical study in Triple negative breast cancer presented at the 47^th Annual San Antonio Breast Cancer Symposium (SABCS-2024) .
09 Dec 2024 Pharmacodynamics data from a preclinical trial in Cancer released by Circle Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com